Menarini Group Announces New Data on ELZONRIS (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
Data spans five abstracts including two oral presentations with important findings for…
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc.…
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – –…
HABANOS, S.A. PRESENTED A WORLD PREMIERE “MONTECRISTO ELBA LIMITED EDITION 2025”
Montecristo celebrates its 90th anniversary with the launch of the new 'Elba'…
Real-World Data Presented at TCT 2025 Demonstrates the EggNest Complete Radiation Protection System Significantly Reduces Radiation Exposure for the Entire Cath Lab Team
SAN FRANCISCO, Oct. 26, 2025 /PRNewswire/ -- At the 2025 Transcatheter Cardiovascular…
Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3K Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglyc
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT…
Paris 2024 Fair Play Awards presented at Olympic Museum
13 October 2025 - Decathlete Sander Skotheim, the German Olympic Sports Confederation (DOSB)…
Tommy Fleetwood of Team Europe wins Nicklaus-Jacklin Award presented by Aon at 45th Ryder Cup
Award given to one outstanding player who embodies the true spirit of…
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results…
New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl…
